Rujia Zheng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Rujia Zheng has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Li Zhou
Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, Department of Infectious Diseases, The Second Affiliated Hospital Chongqing Medical University Chongqing Chongqing China
1 shared publication Qitai Chen
MOE Joint International Research Laboratory of Pancreatic Diseases, Zhejiang Provincial Key Laboratory of Pancreatic Disease, The First Affiliated Hospital Zhejiang University School of Medicine Hangzhou Zhejiang China
1 shared publicationShuaijun Lu
The First Affiliated Hospital of Ningbo University Ningbo Zhejiang China
1 shared publicationXishan Yang
MOE Joint International Research Laboratory of Pancreatic Diseases, Zhejiang Provincial Key Laboratory of Pancreatic Disease, The First Affiliated Hospital Zhejiang University School of Medicine Hangzhou Zhejiang China
1 shared publicationYi Zang
MOE Joint International Research Laboratory of Pancreatic Diseases, Zhejiang Provincial Key Laboratory of Pancreatic Disease, The First Affiliated Hospital Zhejiang University School of Medicine Hangzhou Zhejiang China
1 shared publicationYuJie Yu
ZJU‐Hangzhou Global Scientific and Technological Innovation Center Zhejiang University Hangzhou Zhejiang China
1 shared publication
Latest Publications
- Open Access
- 9 April 2026
- Published by Wiley in MedComm – Oncology
- Vol. 5 (2)
Oxidative Stress and DNA Epigenetic Modifications in Cancer: Mechanisms and Targeted Therapeutics
Oxidative stress, defined as an imbalance between the production and clearance of reactive oxygen species (ROS), is not merely a reflection of metabolic or microenvironmental stress but an active signaling and regulatory hub in cancer. ROS function as key signaling molecules that drive tumorigenesis, metabolic reprogramming, and epigenetic remodeling. However, a systematic view of the spatiotemporally organized, bidirectional crosstalk between ROS and the DNA epigenetic machinery, particularly under conditions such as hypoxia, remains incomplete. This review synthesizes current understanding of this bidirectional axis. We detail how ROS reshape the DNA epigenetic landscape by modulating DNA methyltransferases and ten‐eleven translocation family protein (TET) dioxygenases, altering profiles of 5‐methylcytosine and its oxidized derivatives, and how epigenetic modifications in turn regulate ROS homeostasis through antioxidant and metabolic pathways. We further explore the cascade regulation of this interaction within the hypoxic tumor microenvironment and evaluate combined intervention strategies targeting both redox and epigenetic mechanisms. Emerging therapeutic avenues are highlighted, including spatiotemporally controlled ROS modulation, CRISPR‐based epigenome editing, ROS‐responsive proteolysis‐targeting chimeras, artificial intelligence (AI)‐driven multi‐omics prediction, and tissue‐specific delivery platforms. By integrating these insights, this review provides a framework for developing ROS‐guided precision epigenetic reprogramming strategies, offering novel therapeutic opportunities in cancer.
- 9 April 2026
- Published by Wiley in MedComm – Oncology
- Vol. 5 (2)
Open AccessOxidative Stress and DNA Epigenetic Modifications in Cancer: Mechanisms and Targeted Therapeutics
Oxidative stress, defined as an imbalance between the production and clearance of reactive oxygen species (ROS), is not merely a reflection of metabolic or microenvironmental stress but an active signaling and regulatory hub in cancer. ROS function as key signaling molecules that drive tumorigenesis, metabolic reprogramming, and epigenetic remodeling. However, a systematic view of the spatiotemporally organized, bidirectional crosstalk between ROS and the DNA epigenetic machinery, particularly under conditions such as hypoxia, remains incomplete. This review synthesizes current understanding of this bidirectional axis. We detail how ROS reshape the DNA epigenetic landscape by modulating DNA methyltransferases and ten‐eleven translocation family protein (TET) dioxygenases, altering profiles of 5‐methylcytosine and its oxidized derivatives, and how epigenetic modifications in turn regulate ROS homeostasis through antioxidant and metabolic pathways. We further explore the cascade regulation of this interaction within the hypoxic tumor microenvironment and evaluate combined intervention strategies targeting both redox and epigenetic mechanisms. Emerging therapeutic avenues are highlighted, including spatiotemporally controlled ROS modulation, CRISPR‐based epigenome editing, ROS‐responsive proteolysis‐targeting chimeras, artificial intelligence (AI)‐driven multi‐omics prediction, and tissue‐specific delivery platforms. By integrating these insights, this review provides a framework for developing ROS‐guided precision epigenetic reprogramming strategies, offering novel therapeutic opportunities in cancer.